Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
MOBILion Systems, Inc., based in Chadds Ford, Pa., announced a successful $35 million Series B funding round led by aMoon, with participation from existing investors including Agilent Technologies (NYSE: A). The funds will support the commercial launch of their Structures for Lossless Ion Manipulation (SLIM) technology aimed at enhancing biomarker discovery and diagnostics. The first product is set for full launch in North America in 2021. MOBILion's SLIM technology is expected to improve the characterization of biologic therapeutics and contribute to COVID-19 research.